Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's ...
Had the Dateline NBC vet not gone public with her decision to vacate her Today spot, Hoda Kotb might have been the one ...
A United States postal worker is facing multiple theft charges, including opening mail that didn’t belong to her, after ...
Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
Filming is underway on Netflix's adaptation of Alice Feeney's His & Hers starring Tessa Thompson and Jon Bernthal.
Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.
Fox 4's Austin Schargorodski reports on a Cape Coral woman arrested for trying to sell a boat that wasn’t hers, using forged ...
Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback